Rigel Pharmaceuticals announced that Lisa Rojkjaer retired as Chief Medical Officer on July 1, 2026, and Alison Hannah was appointed as the new CMO the same day. Hannah previously served as Chief Medical Officer at CytomX Therapeutics and Senior Medical Director at Sugen, now part of Pfizer. She stated she looks forward to guiding the continued development of R289 and Rigel's broader clinical strategy, including the recent addition of vepdegestrant. In pre-market activity on Nasdaq, Rigel shares were up 2.25 percent at $40.00, after closing Tuesday's regular session 0.20 percent higher.
Rigel Pharmaceuticals IncAppointment of new CMO to guide development of R289 and vepdegestrant signals continued clinical progress.
CytomX Therapeutics Inc
Pfizer Inc